Retatrutide (30mg Vial) Dosage Protocol

Overview

Concise summary of the once-weekly regimen based on clinical trial protocols.

• Goal: Achieve substantial weight loss (up to 24% of body weight) and improved metabolic parameters through triple receptor agonism^[2][5].
• Schedule: Weekly subcutaneous injections for 12+ weeks with gradual dose escalation.
• Dose Range: 2–12 mg once weekly; clinical trials tested up to 12 mg as the maximum maintenance dose^[1][3].
• Reconstitution: 3.0 mL per 30 mg vial (10.0 mg/mL) provides optimal concentration with minimal waste—the most efficient vial size available.
• Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted solution refrigerated at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks.

What You’ll Need

Plan based on a 12–48 week weekly protocol with gradual titration to maintenance dose.

• Peptide Vials (Retatrutide, 30 mg each): Highly efficient vial size—minimal waste
  • 12 weeks (2→4→8 mg titration): 2 vials
  • 24 weeks (up to 12 mg): 7 vials
  • 48 weeks (maintenance at 12 mg): 17 vials
• Insulin Syringes (U-100, 1 mL):
  • Per week: 1 syringe (once-weekly dosing)
  • 12 weeks: 12 syringes
  • 24 weeks: 24 syringes
  • 48 weeks: 48 syringes
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • 12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
  • 24 weeks (7 vials): 21 mL → 3 × 10 mL bottles
  • 48 weeks (17 vials): 51 mL → 6 × 10 mL bottles
• Alcohol Swabs: One for the vial stopper + one for the injection site each week.
  • Per week: 2 swabs
  • 12 weeks: 24 swabs → 1 × 100-count box
  • 24 weeks: 48 swabs → 1 × 100-count box
  • 48 weeks: 96 swabs → 1 × 100-count box

View Supplier

View Supplier

How to Reconstitute

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl/roll until dissolved (do not shake vigorously).
4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Dosing Schedule

Frequency: Inject once weekly subcutaneously. This schedule follows clinical trial protocols that demonstrated significant weight loss (up to 24% at 48 weeks with 12 mg weekly)^[2] while minimizing gastrointestinal adverse events through gradual escalation^[1][4]. Starting at 2 mg weekly (versus 4 mg) significantly reduces initial GI side effects. The 30 mg vial size with 3.0 mL reconstitution provides excellent concentration (10.0 mg/mL) for convenient measuring. For the maintenance dose (12 mg = 1.20 mL), either split into two 0.60 mL injections at different sites or reconstitute an additional vial.

Protocol Details

Evidence-based weekly titration approach from clinical trials.

• Start: 2 mg once weekly for first 4 weeks to establish tolerability^[1][4].
• Escalation: Increase to 4 mg weekly (Weeks 5–8), then 8 mg weekly (Weeks 9–12)^[1].
• Maintenance: 12 mg weekly (Week 13 onward) for maximum efficacy; 8 mg weekly is an alternative maintenance dose^[2].
• Frequency: Once per week (subcutaneous); consistent day/time recommended.
• Cycle Length: Minimum 12 weeks for titration; clinical trials extended to 48 weeks showing sustained weight loss^[2].
• Timing: Any consistent weekly schedule; rotate injection sites each week.

Storage

Proper storage maintains peptide stability and potency.

• Lyophilized: Store at −20 °C (−4 °F) or colder for long-term preservation; protect from moisture and light^[11][12].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) immediately after mixing; use within 2–4 weeks for maximum potency^[11].
• Handling: Allow frozen vials to reach room temperature before opening to minimize condensation; never expose reconstituted solution to heat or direct sunlight.
• Aliquoting: For extended storage beyond 4 weeks, consider freezing unused aliquots; avoid repeated freeze-thaw cycles^[12].

How Retatrutide Works

Retatrutide is a first-in-class triple agonist that simultaneously activates three key metabolic hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon^[1][5]. This triple mechanism produces synergistic effects on appetite suppression, energy expenditure, and glucose metabolism that exceed single or dual agonists.

The GLP-1 component reduces appetite and slows gastric emptying; GIP enhances insulin secretion and may support fat metabolism; glucagon receptor activation increases energy expenditure and promotes fat oxidation^[5][8]. With an extended half-life of approximately 6 days, retatrutide enables convenient once-weekly dosing while maintaining therapeutic levels^[1].

In clinical trials, participants receiving 12 mg weekly retatrutide lost an average of 24% of their body weight over 48 weeks^[2]. In adults with type 2 diabetes, retatrutide (up to 12 mg weekly) achieved approximately 17% weight loss at 36 weeks alongside HbA1c reductions of approximately 2.0% compared to placebo^[3]. A 2025 meta-analysis of three trials (878 participants) confirmed retatrutide achieved significantly greater weight reduction than placebo (mean difference approximately 14% of body weight) with no significant increase in overall adverse events^[6][7].

Good to Know

• Weekly consistency: Choose a specific day/time for your weekly injection and maintain this schedule throughout the protocol.
• Gradual titration is essential: Starting at 2 mg weekly (versus higher doses) significantly reduces initial gastrointestinal side effects^[4].
• Efficient vial size: The 30 mg vial provides excellent value with minimal waste—only 2 vials needed for the first 12 weeks of titration.
• Use new sterile insulin syringes for each injection; dispose immediately in a puncture-proof sharps container^[14].
• Rotate injection sites weekly (abdomen, thighs, upper arms) at least 1 inch apart to prevent local irritation or lipohypertrophy^[15].
• For the 12 mg maintenance dose (1.20 mL), either split into two 0.60 mL injections at different sites or use a second vial for the remaining volume.
• Monitor for gastrointestinal side effects (nausea, diarrhea); if severe, consider extending the time at current dose before escalating.
• Substantial weight loss: Up to 24% reduction in body weight at 48 weeks with 12 mg weekly dosing^[2].
• Glycemic improvement: Significant HbA1c reductions (approximately 2.0%) in adults with type 2 diabetes^[3].
• Metabolic benefits: Improvements in lipid profiles, blood pressure, and cardiovascular risk markers^[1][5].
• Convenient dosing: Once-weekly subcutaneous administration improves adherence compared to daily regimens^[1].
• Gastrointestinal effects: Nausea, diarrhea, vomiting, and constipation are the most common adverse events; typically mild-to-moderate and diminish over time^[2][4].
• Starting at 2 mg weekly (versus 4 mg) significantly reduces initial GI adverse events^[4].
• Injection site reactions: Mild redness, swelling, or discomfort at injection sites may occur; rotate sites to minimize.
• Overall safety profile: Meta-analysis found no significant increase in overall adverse events compared to placebo^[6][7].

Tips for Best Results

Complementary strategies to optimize outcomes during retatrutide protocols.

• Nutrition: Adopt a balanced, protein-forward diet (1.0–1.2 g/kg body weight) to preserve lean mass during weight loss^[10].
• Hydration: Maintain adequate fluid intake, especially during dose titration when GI effects are most common.
• Physical activity: Combine resistance training (2–3×/week) with moderate aerobic exercise to support metabolic adaptations and preserve muscle mass.
• Sleep & stress: Prioritize 7–9 hours of quality sleep and implement stress management techniques to support hormonal balance and adherence.
• Meal timing: Some individuals find smaller, more frequent meals help manage GI side effects during initial titration.

Injection Tips

• Clean the vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully before proceeding.
• Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose precisely.
• Pinch a fold of skin and insert the needle at 45° into subcutaneous fat (90° is acceptable with a short needle into a well-pinched fold).
• Inject slowly over 2–3 seconds; do not aspirate. Withdraw the needle, apply gentle pressure, and do not rub the site.
• Rotate injection sites (abdomen, thighs, upper arms) and dispose of each syringe in a sharps container immediately after use.

Related Reading

Learn more about the peptides in this protocol:

• What Is Retatrutide?
• Retatrutide vs. Tirzepatide
• What Is Semaglutide?
• What Is Tirzepatide?
• Peptide Dosage Calculator